Alise Reicin
CEO
Tectonic Therapeutic
Tectonic Therapeutic is a clinical-stage biotechnology company that utilizes its proprietary GEODe™ platform to discover and develop therapeutic proteins and antibodies targeting G-Protein Coupled Receptors (GPCRs). The company focuses on creating biologic medicines for conditions with significant unmet medical needs, where existing therapeutic options are limited or absent.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$130.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
G-Protein Coupled Receptors (GPCRs) are critical drug targets, but developing biologic medicines against them has been historically challenging. Many conditions with significant unmet medical needs lack effective therapeutic options due to these challenges in GPCR-targeted drug discovery.
Solution
Tectonic Therapeutic is developing therapeutic proteins and antibodies that modulate GPCR activity to address diseases with limited or nonexistent treatment options. The company's GEODe™ platform facilitates the discovery and development of GPCR-targeted biologics, overcoming previous limitations in the field. By focusing on biologics, Tectonic aims to achieve selectivity profiles and multi-modal actions that are difficult to attain with traditional small molecule drugs. This approach allows for the creation of novel therapies that can modify the course of disease and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from conditions with significant unmet medical needs, particularly those where existing therapeutic options are poor or nonexistent, as well as the healthcare providers who treat them.
Features
- GEODe™ platform for GPCR-targeted biologic medicine discovery
- Focus on biologics to achieve enhanced selectivity and multi-modal action compared to small molecules
- Development programs targeting first-in-indication opportunities
- TX45 development for Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Expertise in GPCR biochemistry and biophysics to translate basic research into novel therapies